Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

INSIDE INFORMATION
(I) POSSIBLE DELAY IN PUBLICATION OF 2026 INTERIM RESULTS; (II) POSSIBLE DELAY IN DESPATCH OF 2026 INTERIM REPORT; AND (III) CONTINUED SUSPENSION OF TRADING

This announcement is made by Sunho Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Company's announcement dated May 3, 2026 (the "**Resumption Guidance Announcement**") in relation to, among other things, a letter from the Stock Exchange setting out the guidance (the "**Resumption Guidance**") for the resumption of trading in the shares of the Company (the "**Shares**") on the Stock Exchange. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Resumption Guidance Announcement.

POSSIBLE DELAY IN PUBLICATION OF 2026 INTERIM RESULTS

Pursuant to Rule 13.49(6) of the Listing Rules, the Company is required to publish the interim results of the Group for the six months ended June 30, 2026 (the "**2026 Interim Results**") on a date not later than two months after the end of that period of six months (i.e., not later than August 31, 2026). Further, pursuant to Rule 13.43 of the Listing Rules, an issuer is required to publish an announcement at least seven clear business days in advance of the date fixed for any board meeting at which the results for any financial period are to be approved for publication.

As the publication of the 2025 Annual Results is still pending, and the 2026 Interim Results will be published after the publication of the 2025 Annual Results. Based on the information currently available, it is expected that the publication of the 2026 Interim Results will be delayed beyond August 31, 2026, and the Board is currently unable to determine a date for the board meeting (the "**Board Meeting**") to approve the publication of the 2026 Interim Results.

POSSIBLE DELAY IN DESPATCH OF 2026 INTERIM REPORT

Pursuant to Rule 13.48(1) of the Listing Rules, the Company is required to publish its interim report for the six months ended June 30, 2026 (the "**2026 Interim Report**") on a date not later than three months after the end of that period of six months (i.e., not later than September 30, 2026). Due to the possible delay in publication of the 2026 Interim Results, the despatch of the 2026 Interim Report is also likely to be delayed.

The Company will publish further announcement(s) to inform its shareholders (the "**Shareholders**") and potential investors of (i) the date of the Board Meeting; (ii) the date of the publication of the 2026 Interim Results; and (iii) the despatch of the 2026 Interim Report, as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will remain suspended until the Company meets all Resumption Guidance, remedies the issues causing its trading suspension, and fully complies with the Listing Rules to the Stock Exchange's satisfaction.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, August 26, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.